Sarilumab sar153191    (DrugBank: Sarilumab, SAR153191)

1 disease
IDDisease name (Link within this page)Number of trials
41Giant cell arteritis1

41. Giant cell arteritis    [ 108 clinical trials,   111 drugs,   (DrugBank: 32 drugs),   33 drug target genes,   121 drug target pathways]
Searched query = "Giant cell arteritis", "Temporal arteritis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 108 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03600805
(ClinicalTrials.gov)
November 20, 201817/7/2018Evaluation of Efficacy and Safety of Sarilumab in Patients With GCAA Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell ArteritisGiant Cell ArteritisDrug: Sarilumab SAR153191;Drug: Sarilumab matching placebo;Drug: Prednisone;Drug: Prednisone matching placeboSanofiRegeneron PharmaceuticalsSuspended50 YearsN/AAll360Phase 3United States;Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;Estonia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Russian Federation;Slovenia;Spain;Sweden;Switzerland;United Kingdom